Tevard, Zogenix Partner to Advance Gene Therapies for Genetic Epilepsies

Tevard, Zogenix Partner to Advance Gene Therapies for Genetic Epilepsies

281936

Tevard, Zogenix Partner to Advance Gene Therapies for Genetic Epilepsies

Tevard Biosciences and Zogenix announced entering a collaboration agreement to advance potential gene therapies for genetic epilepsies, including Dravet syndrome. “We are pleased to announce our collaboration with Zogenix, whose commitment to developing new treatments for Dravet syndrome and other genetic epilepsies is unparalleled,” Daniel Fischer, co-founder, president and CEO at Tevard, said in a press release. Dravet syndrome is caused by a loss-of-function mutation in one copy of the SCN1A gene, which codes for part…

You must be logged in to read/download the full post.